Labs become far more useful when they are read as a pattern over time, next to what you are actually experiencing, by a clinician who knows your history.
Perimenopause is the stretch of years when the ovaries lose their cycle-to-cycle consistency, and the hormone signals driving the menstrual cycle become erratic rather than simply low. It is a transition, not a switch.
Every ovary starts with a finite pool of follicles, and that pool shrinks steadily across adult life. As fewer follicles remain and the ones that do respond less predictably, two things happen. Cycles start to vary in length, sometimes shortening before they lengthen, and the hormone output of each cycle becomes uneven. Estradiol, the main form of estrogen produced by a growing follicle, does not simply fall in a straight line. It can spike higher than it ever did in your twenties during a cycle where the ovary is working hard, then drop sharply in the next.
That volatility explains most of the symptom experience. Hot flushes, night sweats, broken sleep, mood changes, heavier or lighter bleeding, cycle irregularity and the mental fuzziness many people describe tend to track the swings rather than any one absolute level.
Menopause itself is defined backwards, as the point twelve months after the final menstrual period. You only know you reached it once a year has passed. Everything before that twelve-month mark, with symptoms and changing cycles, is the perimenopausal window, and it can run for several years.
FSH is a hormone released by the pituitary gland that tells ovarian follicles to grow and mature. It is part of a feedback loop. When ovarian output of estradiol and inhibin B is strong, the pituitary eases off. When ovarian output falls, the pituitary pushes harder and FSH rises.
That is why FSH is the marker most often ordered when someone asks about the menopausal transition. It is an indirect readout of how much the brain is having to shout to get a response.
The full detail on what this marker measures, how the sample is taken and how to read a number on a report lives on the FSH biomarker page linked above. The rest of this guide stays on the question you came with, which is what hormone testing can and cannot tell you about perimenopause.
No. For most people in the typical age window, the transition is identified from symptoms and cycle changes, not from a lab value. Guidance on menopause diagnosis summarised in the BMJ advises diagnosing perimenopause in women over 45 from vasomotor symptoms and irregular periods without laboratory testing, and reserving FSH measurement for women aged 40 to 45 with symptoms and a change in cycle, and for those under 40 where early loss of ovarian function is suspected 1.
The reason is practical rather than philosophical. Research suggests that, during the menopausal transition, FSH values overlap substantially between women who are still cycling normally and those well into the change, which limits how much a single measurement can settle 2.
This is the opposite of how most people expect lab testing to work. With many markers, a number sits outside a reference range and points somewhere specific. With reproductive hormones in this phase, the number is a frame from a film that is still running. One frame can be misleading.
That does not make testing pointless. It changes what you ask of it. A hormone panel is useful for building context, for flagging other explanations for your symptoms, and for giving a clinician a baseline to compare against later. It is not useful as a yes or no verdict, and a result that looks ordinary does not mean your symptoms are imaginary.
They swing because the feedback loop between ovary and pituitary loses its damping, not because the ovary simply switches off. Understanding the mechanism makes an odd-looking result much less confusing.
In a stable cycle, a cohort of follicles grows, the dominant one produces estradiol and inhibin B, and those signals tell the pituitary to hold FSH down. As the follicle pool thins, inhibin B output falls first. With less of that restraint, FSH drifts upward, particularly in the early part of the cycle. Higher FSH then recruits whatever follicles remain more aggressively, and if a capable follicle responds, it can generate a large burst of estradiol. That burst suppresses FSH again, sometimes back into a range that looks entirely unremarkable.
Research suggests that across the transition FSH rises while inhibin falls, with estradiol often maintained or even elevated until relatively late in the process 2. So you can have a month with high FSH and low estradiol, followed by a month with the reverse pattern, while the underlying trajectory has not changed at all.
Practically, this means three things. Timing of the draw matters. A single value carries limited weight. And symptoms that come and go in waves are consistent with the biology rather than a sign against it.
FSH is reported in milli-international units per millilitre, and most laboratories publish a broad reference range for adults of reproductive age that narrows or widens depending on cycle phase and assay.
| Marker | Typical lab reference range | FitScript optimal range |
|---|---|---|
| FSH (follicle-stimulating hormone) | 1 to 15 mIU/mL | 1.5 to 10 mIU/mL |
Typical lab reference ranges vary by laboratory, age, sex and point in the cycle, so always read your own report against the range printed on it. FitScript's optimal range is an optimization target, not a diagnostic cut-off, and sitting outside it does not establish any condition.
Two cautions make these numbers easier to use. First, laboratories differ in the assay they run, so a value from one lab is not perfectly interchangeable with a value from another. Comparing results over time is cleanest when they come from the same laboratory. Second, a cycling person tested on day three of a period is being measured at the point in the month where FSH is normally at its baseline, while the same person tested mid-cycle may show a very different figure for entirely ordinary reasons.
After the final menstrual period, FSH typically settles at a much higher level and stops swinging, because there is no longer meaningful ovarian feedback holding it down. That steadiness, rather than any single threshold, is often the more informative signal.
A raised FSH suggests the pituitary is pushing harder to get an ovarian response, which commonly happens as the follicle pool declines. That is an observation, not a diagnosis.
The inference depends on everything around the number. In someone in their late forties with irregular cycles, night sweats and disturbed sleep, a raised FSH fits the broader picture and adds modest support to what the symptoms already suggest. In someone in their early thirties with regular cycles, the same value would prompt a clinician to repeat the test and look more carefully for other explanations rather than to conclude anything from one draw.
A raised value can also reflect timing. Blood taken in the few days around a cycle where the ovary responded poorly can read high, while the next cycle reads lower. This is why clinicians rarely act on an isolated elevated result and often repeat it after a few weeks.
The useful next step after a raised FSH is a conversation rather than a conclusion. Worth discussing with a clinician are the age at which it appeared, the cycle pattern around it, whether symptoms are affecting daily function, and whether other markers that cause overlapping symptoms have been checked. A result that is substantially outside the standard range in someone under 40 is worth discussing with a clinician promptly, because the evaluation in that age group is different.
An in-range FSH does not rule out perimenopause. This is probably the single most useful thing to know about hormone testing in this phase.
Because FSH is suppressed whenever a follicle produces a decent surge of estradiol, a blood draw taken in that part of the cycle can land squarely in the middle of the reference range in someone whose cycles have been chaotic for a year. Research suggests that the overlap in FSH values between women at different stages of the transition is wide enough to limit the diagnostic weight of any single measurement 2, which is exactly the situation an unremarkable result describes.
The practical response is not to dismiss the result or the symptoms. It is to change what you rely on. Guidance summarised in the BMJ places the emphasis for women over 45 on the symptom and cycle picture rather than on laboratory values 1, so a careful symptom history carries more weight than a reassuring number.
It is also a prompt to check what else could be producing the same experience. Fatigue, low mood, poor sleep, weight change and cognitive fog are not specific to reproductive hormones, and several other markers can produce an overlapping picture. Ruling those in or out is more valuable than repeating the same hormone test hoping for a different answer.
Anti-Mullerian hormone is produced by small growing follicles, so it reflects the size of the remaining follicle pool and, unlike FSH, varies relatively little across the menstrual cycle. That stability is what makes it attractive as a marker in this conversation.
A systematic review of AMH for the diagnosis and prediction of menopause found that lower AMH is associated with a shorter time to the final menstrual period, while individual-level prediction remained imprecise 3. In other words, AMH tracks the direction of travel better than the arrival date.
Work on the utility of AMH in predicting menopause suggests that it adds information beyond age alone but does not deliver a reliable personal timeline 4. A narrative review asking whether AMH is a marker of upcoming menopause or guesswork reached a similarly cautious position about how much weight a single value can carry 5.
So where does that leave someone with a result in hand. A low AMH alongside irregular cycles and symptoms is one more piece of a consistent picture. A low AMH on its own, in someone with regular cycles and no symptoms, is not a countdown clock, and it should not be read as one. AMH is also measured on different assay platforms whose numbers do not always align, which is another argument for interpreting it with a clinician rather than against a figure found online.
The three markers move in a characteristic sequence rather than all at once, and knowing the sequence explains most confusing panels. Inhibin declines, FSH rises in response, and estradiol holds up longer than people expect.
Research suggests that, during the menopausal transition, falling inhibin accompanies rising FSH while estradiol concentrations are often preserved until a late stage 2. This is why a panel showing elevated FSH with a perfectly respectable estradiol is not contradictory. It is the expected middle of the sequence.
It also explains symptoms that seem to point in opposite directions. Breast tenderness, heavier bleeding and fluid retention can accompany the high-estradiol stretches, while hot flushes and sleep disruption often cluster around the drops. Someone can experience both within a single season.
For interpretation, the implication is that no one marker in this group should be read alone, and that the direction of change across repeated panels tells you more than any absolute figure. Two panels six months apart, taken at a comparable point in the cycle and run by the same laboratory, give a clinician far more to work with than one comprehensive snapshot.
Markers that produce overlapping symptoms are worth checking alongside reproductive hormones, because the experience of perimenopause is non-specific and more than one thing can be true at once.
The common companions in a workup include estradiol and luteinising hormone for cycle context, thyroid markers, iron status including ferritin, markers of glucose regulation, a lipid panel and vitamin D. Fatigue, cognitive fog, hair thinning, low mood and temperature intolerance all appear on more than one of those lists, and sorting them out by symptom alone is unreliable.
There is a second reason to look wider. The menopausal transition is a period when cardiometabolic and bone-related measures shift, so a broader baseline taken now gives a clinician something to compare against in later years rather than starting from scratch at 55.
FitScript tests 150+ biomarkers per year and has Atlas, its AI health advisor, read results against a member's symptom history, with any treatment decision belonging to a licensed provider who reviews the person first.
What matters most for you is that the panel is chosen around your actual complaints and history rather than ordered as a reflex, and that someone qualified interprets the whole set together rather than reacting to one flagged line.
If you are still having periods, FSH and estradiol are usually drawn in the early follicular phase, around days two to five of the cycle, counting the first day of full flow as day one. That timing gives the most comparable baseline from one cycle to the next.
The test itself is a standard venous blood draw, often in the morning, and it is quick. Fasting is not required for FSH, although other markers run on the same sample may call for it, so follow the instructions attached to your requisition. If your cycles have become unpredictable or have stopped, early-follicular timing no longer applies and the draw is taken when convenient, which is one more reason to interpret the value loosely.
At-home finger-prick kits for reproductive hormones exist and can be convenient. The sample type and assay can differ from a laboratory venous draw, so results are not always directly comparable, and any result you intend to act on is worth confirming through a clinician.
One habit improves every comparison you will make later. Record the date of your last period, the cycle day of the draw, the laboratory used and the symptoms you were having that month. Without those four pieces of information, repeat testing later is much harder to interpret, because you cannot tell whether a change reflects your biology or just a different point in the month.
Several ordinary factors shift reproductive hormone values, which is why a surprising number is a reason to repeat and review rather than to conclude.
Cycle timing is the largest one. A draw taken mid-cycle or in the luteal phase is measuring a different part of the loop than a day-three draw. Acute illness, significant physical or psychological stress, heavy training loads and substantial recent weight change can all influence the signalling between brain and ovary. Some medicines also affect these results, so ask your prescriber whether anything you take could alter them before drawing conclusions.
Body composition and metabolic status belong on the list too. Work on the signalling links between FSH and metabolism describes connections between this hormone and metabolic tissue beyond the ovary, which suggests the relationship runs in more than one direction 6.
Finally, assay variation is real. Different platforms produce different absolute numbers for the same sample, so a value from a new laboratory that looks like a dramatic shift may partly reflect the change in method. Keeping testing with one laboratory removes a layer of noise you would otherwise have to argue with.
There is reason to think FSH signalling touches tissues outside the reproductive system, which is part of why this marker attracts interest beyond the question of cycle status.
Evidence suggests that FSH has extragonadal effects relevant to bone and cardiovascular biology in women during the menopausal transition 7. Separate work describing FSH and metabolic circuitry points to connections between this hormone and metabolic regulation around the same life stage 6.
The honest framing is that this describes connections rather than instructions. Nobody should read an FSH value as a measure of bone or heart health, and no single marker carries that weight. What it supports is the broader point that the menopausal transition is a whole-body shift rather than a reproductive footnote, and that a wider baseline taken during these years is worth having.
If bone or cardiometabolic health is a concern for you, those questions have their own dedicated measures, and which ones are appropriate is a decision for your clinician based on your age, history and risk profile.
Repeat testing is useful when it is spaced widely enough to show a trend and timed consistently enough to be comparable. Re-testing every few weeks because one value looked odd usually generates confusion rather than clarity.
A reasonable approach, agreed with your clinician, is to retest at an interval of several months, at a comparable cycle day where that is still possible, at the same laboratory, with a record of symptoms for each period in between. If the symptom picture changes substantially or something new appears, that is a better trigger for retesting than the calendar.
In the age group where guidance already favours a symptom-based assessment, repeated testing often adds little to the decisions in front of you. The value of serial testing is higher when there is genuine uncertainty, such as symptoms appearing unusually early or a clinical picture that does not fit.
A symptom diary is an underrated companion to any of this. Cycle length, bleeding pattern, sleep quality, flushes, mood and cognitive clarity tracked over a few months give a clinician more signal than another blood draw, and they cost nothing.
Any symptom that is interfering with sleep, work, relationships or daily function is enough reason, regardless of what a lab result says. You do not need an abnormal number to justify the conversation.
Some situations deserve prompt attention rather than a wait-and-see approach. Bleeding that is unusually heavy or prolonged, bleeding between periods, bleeding after sex, and any bleeding that occurs after twelve months without a period are all worth discussing with a clinician promptly. So are symptoms of the transition appearing before age 40, because the assessment in that age group follows a different path 1. Sudden severe mood changes, or thoughts of harming yourself, warrant immediate medical help.
Bring four things to the appointment. Your cycle history over the past year, your symptom pattern, any previous results with their dates and the laboratory used, and a list of what you take regularly so your prescriber can account for anything that influences results. That turns a vague conversation into a specific one.
This page is educational and not medical advice. Discuss your results, your symptoms and any next step with a clinician or licensed provider who can assess your full history, and remember that treatment decisions belong to a licensed provider.
For a wider view of the experience itself, see the guide to perimenopause symptoms, the explainer on when does perimenopause start, the background on average menopause age, and the deeper look at brain fog perimenopause.
No single blood test confirms it. For most people over 45, the assessment is based on age, cycle changes and symptoms rather than on a lab value. Hormone results can add context, but they are read alongside your history, not instead of it.
FSH is the one most often ordered, usually with estradiol, because it reflects how hard the pituitary is signalling the ovaries. AMH is sometimes added since it changes less across the month. Which markers make sense for you is a decision for your clinician.
If you are still having periods, the draw is usually taken in the early follicular phase, roughly days two to five, counting the first day of full flow as day one. That timing makes results comparable from one cycle to the next. If your cycles have stopped or become unpredictable, timing matters less and the result should be interpreted loosely.
Yes. FSH drops back whenever a follicle produces a good surge of estradiol, so a draw taken in that part of the cycle can look entirely ordinary. An in-range result does not rule out the transition and does not mean your symptoms lack a cause.
It suggests the pituitary is pushing harder to get a response from the ovaries, which is common as the follicle pool declines. On its own it does not establish any condition, and it is interpreted against your age, cycle pattern and symptoms. A clinician may repeat the test before drawing any conclusion.
Not with any precision. AMH reflects the size of the remaining follicle pool and tracks the general direction of travel, but it does not give a reliable personal date. Treat it as one piece of context rather than a countdown.
They are convenient, but the sample type and assay can differ from a venous laboratory draw, so results are not always directly comparable. If a home result would change what you do next, confirm it through a clinician. Keeping all your testing with one laboratory also makes comparison over time much cleaner.
Whenever symptoms are affecting your sleep, work or daily life, regardless of what a result says. Speak to a clinician promptly about bleeding that is unusually heavy or prolonged, bleeding between periods, bleeding after sex, any bleeding after twelve months without a period, or symptoms starting before age 40. Any next step, including treatment, is decided by a licensed provider.